Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.
Trial Details
- NCT ID
- NCT06236724
- Phase
- PHASE2
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Cancer Type
- Chronic Myeloid (CML) Leukemia
- Interventions
- Locations (sample)
- Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
- Adult participants age ≥18 years.
- Participants must have a diagnosis of Ph-positive or BCR::ABL1 positive CML in early chronic phase (i.e., time from diagnosis ≤12 months).
- Participants who received prior hydroxyurea, 1 to 2 doses of cytarabine, and/or an FDA approved TKI for \<30 days are eligible.
- Participants with additional chromosomal abnormalities at diagnosis (early disease) and no other criteria for accelerated phase will be eligible fo…
For full eligibility, visit ClinicalTrials.gov.